The burgeoning landscape of medication for obesity and type 2 metabolic disorder is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 https://roberteolm290938.theideasblog.com/39410972/retatrutide-vs-tirzepatide-a-comparative-analysis